Scrip: industry news and insights
Almirall Views Vitiligo As Next Dermatology Opportunity
By Kevin Grogan 18 May 2022
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a...
French biotech Deinove has acquired, through a contribution-in-kind transaction, the entire capital of Austrian biotech Biovertis AG and its wholly owned German subsidiary Morphochem AG. The deal also provides Deinove with MCB3837, an IV compound developed by Morphochem to treat severe gastrointestinal infections cause by Clostridium difficile which is currently ipoised to enter Phase II.
Under the terms of the deal, Biovertis and Morphochem shareholders will receive 500,001 Denoive shares – worth about €900,000 – although there is the potential for them to eventually own 8m shares should a series of regulatory milestones be reached, valuing the deal at €14.4m. Biovertis and Morphochem have between them raised more than $96m in venture funding.
While declining to give details of how the valuations were calculated, TVM Capital managing partner Hubert Birner confirmed to Scrip that it would be taking a haircut on the deal. This is one of the last transactions for TVM LSV V which was raised in 2001. We continue to do life science investments, of course, with our current fund TVM LSV VII,” he told Scrip. TVM will owned 82.98% of the newly acquired Denoive shares.
Scrip: industry news and insights
By Kevin Grogan 18 May 2022
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a...
Scrip: industry news and insights
18 May 2022
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking...
Scrip: industry news and insights
18 May 2022
Despite promising clinical data and solid regulatory plans, biotech firms hoping to address the unmet need in Sanfilippo Syndrome through...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: